Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

Abstract Background This retrospective study was undertaken to determine if the plasma circulating tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid tumors affected the detection of genomic alterations (GAs) by a plasma ctDNA assay. Method Cell-free DNA (cfDNA) ex...

Full description

Bibliographic Details
Main Authors: Cathy Zhou, Zilong Yuan, Weijie Ma, Lihong Qi, Angelique Mahavongtrakul, Ying Li, Hong Li, Jay Gong, Reggie R. Fan, Jin Li, Michael Molmen, Travis A. Clark, Dean Pavlick, Garrett M. Frampton, Brady Forcier, Elizabeth H. Moore, David K. Shelton, Matthew Cooke, Siraj M. Ali, Vincent A. Miller, Jeffrey P. Gregg, Philip J. Stephens, Tianhong Li
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Journal of Hematology & Oncology
Subjects:
Next-generation sequencing (NGS)
Plasma
Cell-free DNA (cfDNA)
Circulating tumor DNA (ctDNA)
Genomic alterations (GAs)
Maximum somatic allele frequency (MSAF)
Online Access:http://link.springer.com/article/10.1186/s13045-018-0671-8

Internet

http://link.springer.com/article/10.1186/s13045-018-0671-8

Similar Items